Patient characteristics
| HCT patient characteristics . | n = 120 . |
|---|---|
| Median patient age, y (range) | 49 (19-66) |
| Median donor age, y (range) | 48 (15-74) |
| Primary disease | |
| Acute lymphoblastic leukemia | 9 (8%) |
| Acute myelogenous leukemia | 37 (31%) |
| Chronic lymphocytic leukemia | 8 (7%) |
| Chronic myelogenous leukemia | 10 (8%) |
| Hodgkin disease | 2 (1%) |
| Myelodysplastic syndrome | 8 (7%) |
| Myelofibrosis | 3 (2%) |
| Multiple myeloma | 18 (15%) |
| Mantle cell lymphoma | 8 (7%) |
| Non-Hodgkin lymphoma | 13 (11%) |
| Severe aplastic anemia | 4 (3%) |
| Conditioning | |
| Myeloablative | 52 (43%) |
| Nonmyeloablative | 68 (57%) |
| Donor | |
| Related–HLA identical | 92 (77%) |
| Unrelated–HLA identical | 25 (21%) |
| Unrelated–HLA mismatch | 3 (2%) |
| Graft | |
| Bone marrow | 8 (7%) |
| Peripheral blood stem cell | 112 (93%) |
| HCT patient characteristics . | n = 120 . |
|---|---|
| Median patient age, y (range) | 49 (19-66) |
| Median donor age, y (range) | 48 (15-74) |
| Primary disease | |
| Acute lymphoblastic leukemia | 9 (8%) |
| Acute myelogenous leukemia | 37 (31%) |
| Chronic lymphocytic leukemia | 8 (7%) |
| Chronic myelogenous leukemia | 10 (8%) |
| Hodgkin disease | 2 (1%) |
| Myelodysplastic syndrome | 8 (7%) |
| Myelofibrosis | 3 (2%) |
| Multiple myeloma | 18 (15%) |
| Mantle cell lymphoma | 8 (7%) |
| Non-Hodgkin lymphoma | 13 (11%) |
| Severe aplastic anemia | 4 (3%) |
| Conditioning | |
| Myeloablative | 52 (43%) |
| Nonmyeloablative | 68 (57%) |
| Donor | |
| Related–HLA identical | 92 (77%) |
| Unrelated–HLA identical | 25 (21%) |
| Unrelated–HLA mismatch | 3 (2%) |
| Graft | |
| Bone marrow | 8 (7%) |
| Peripheral blood stem cell | 112 (93%) |
Patient characteristics of 120 patients with various leukemic diseases are described. These patients were screened for NuSAP1 and CHAF1b antibodies using quantitative IgG ELISA.